Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

Participants needed: 3
Trial details
Phase: Early Phase 1Age: 18-35Biological sex: AllType: InterventionalSponsor: Shenzhen HemogenUpdated: Nov 29, 2024Locations: 1
Eligibility criteria

Aged 18-35 years (inclusive), ICF can be provided by the patient and/or legal gu... [+6]

Patients with fully HLA-matched donors; [+18]

Read more
Status: Recruiting

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients

Participants needed: 3
Trial details
Phase: Early Phase 1Age: 12-35Biological sex: AllType: InterventionalSponsor: Shenzhen HemogenUpdated: Nov 29, 2024Locations: 1
Eligibility criteria

Aged 12-35 years (inclusive), ICF can be provided by the patient and/or legal gu... [+6]

Patients with fully HLA-matched donors; [+18]

Read more
Status: Recruiting

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

Participants needed: 10
Trial details
Phase: Early Phase 1Age: 8-16Biological sex: AllType: InterventionalSponsor: Shenzhen HemogenUpdated: Nov 29, 2024Locations: 1
Eligibility criteria

8-16 years old. Subject and/or subject's legal guardian fully understand and vol... [+3]

The physical condition does not meet the requirements for hematopoietic stem cel... [+4]

Read more
Status: Recruiting

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

This is a single-arm, open label, multi-center, single-dose Phase 1 clinical trial in subjects with transfusion dependent β-thalassaemia. The study aims to evaluate the safety and efficacy of autologous lentiviral-transduced CD34+ human hematopoietic stem cells (hHSCs) using the gene therapy product HGI-001.

Participants needed: 8
Trial details
Phase: Phase 1Age: 6-35Biological sex: AllType: InterventionalSponsor: Shenzhen HemogenUpdated: Oct 23, 2024Locations: 3
Eligibility criteria

Aged 6-35 years (inclusive), ICF can be provided by the patient and/or legal gua... [+6]

Patients with fully HLA-matched donors; [+16]

Read more